Scientists from Gwangju Institute of Science and Technology in Korea have discovered compound 11c, a potentially ground-breaking oral treatment for metabolic dysfunction-associated steatohepatitis. Their research signals a transformative leap in liver disease management, addressing both inflammation and fibrosis. 11c exhibited potent anti-inflammatory and fibrotic… Read More
CAMP4 Therapeutics has dosed the first participant in its Phase I clinical study of CMP-CPS-001, a potential first-in-class therapeutic for the treatment of urea cycle disorders (UCDs). UCDs are a group of rare, severe, inherited metabolic diseases impacting protein metabolism. Mutations in genes encoding urea cycle… Read More
Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon. The Phase Ib study examined the… Read More
Biotechnology company ImmunAbs has announced the successful completion of a Phase I clinical trial for IM-101, a humanised monoclonal antibody targeting complement C5. The complement system is widely acknowledged for its critical involvement in autoimmune diseases. The randomised, double-blind, placebo-controlled trial was conducted to… Read More
Fibrocor Therapeutics has entered into a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) to advance its Alport Syndrome programme. The agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover… Read More
Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3002 in healthy participants and… Read More
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. CS1002 increases the activation and proliferation of… Read More
CureLab Oncology’s DNA vaccine Elenagen, in combination with chemotherapy, has demonstrated promising clinical results against triple-negative ovarian cancer. The study shows that disease progression was significantly delayed in a group of stage III and IV platinum-resistant ovarian cancer (PROC) patients who received gemcitabine in combination with… Read More
Arvinas has commenced dosing in the Phase I clinical trial of ARV-102, its first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which… Read More
A drug derived from oleic acid – which naturally occurs in animal and vegetable fats such as olive oil – has shown promise for patients with brain cancer, following a study led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK. Results… Read More
DDW Editor Reece Armstrong speaks to Dr Paul Song, MD, NKGen and Dr Vince DeOrchis, clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. In October 2023, pharmaceutical company NKGen Biotech… Read More
Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000, participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg). Read More
Cell and gene therapy company Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical Phase I/II study CARMA in patients with B-cell lymphoma who no longer respond to standard treatment or have relapsed. CARMA is a single-arm, unblinded, multicentre study… Read More
The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The Mobilize trial is run in partnership between Imperial College London and… Read More
Biomica has completed enrolment in its Phase I trial evaluating the safety and tolerability of its microbiome-based immuno-oncology drug, BMC128. Initiated in July 2022, the Phase I trial was designed to evaluate BMC128 in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small… Read More
Italy-based Resalis Therapeutics has closed a €10 million ($11 million) Series A financing round led by Sunstone Life Science Ventures with participation from existing investors. The company intends to use the proceeds to initiate and complete the first-in-human Phase I clinical trial and reach Phase II… Read More
